Semaglutide for use in medicine
AssigneeNovo Nordisk A/S
InventorsMorten Hansen, Martin Linder, Carl Richard Torstenson, Mads Sundby Palle, Lars Holm Damgaard
Life of this patent
Estimating the term…
Abstract
The present invention is directed to use of the GLP-1 receptor agonist semaglutide in medical therapy for the treatment of non-alcoholic steatohepatitis.
Claims30
A method of treating non-alcoholic steatohepatitis (NASH), comprising administering semaglutide subcutaneously in an amount of about 1.7 mg per week to a subject diagnosed with NASH, wherein the administering results in an improvement in lobular inflammation.
A method of treating non-alcoholic steatohepatitis (NASH), comprising administering semaglutide subcutaneously in an amount of about 1.7 mg per week to a subject diagnosed with NASH, wherein the administering results in resolution of NASH and no worsening of liver fibrosis.
A method of treating non-alcoholic steatohepatitis (NASH), comprising administering semaglutide subcutaneously in an amount of about 2.4 mg per week to a subject diagnosed with NASH, wherein the administering results in resolution of NASH and no worsening of liver fibrosis.
Dependencies are inferred from the claim text.